 Michael Kalos, PhD, director of the Clinical Immunobiology Correlative Studies Laboratory, works on the very frontiers of science and medicine. Your support helps carry his research from the lab to the hospital. |
At City of Hope, we are driven to do research and create therapies that can be delivered to the patient as quickly and safely as possible.”
It’s a simple statement of fact. But with it, Michael Kalos, PhD, defines what sets City of Hope apart, and why your generosity makes a real, tangible difference in the lives of people fighting cancer.
Dr. Kalos is director of the Clinical Immunobiology Correlative Studies Laboratory, part of City of Hope’s Cancer Immunotherapeutics and Tumor Immunology, or CITI, program.
It’s a mouthful of a title. But it encompasses some very important ideas about how science and medicine can work hand-in-hand to help cancer patients’ own bodies beat the disease that is attacking them.
Immunotherapy uses the body’s immune system to fight cancer. Research being led by City of Hope’s Dr. Michael Jensen, for example, is uncovering ways to genetically modify T-cells from a patient’s own body, turning them into supercharged cancer fighters. Reinjected into the patient’s body, they could destroy cancerous cells with minimal side-effects on the rest of the body.
“Immunobiology correlative studies” measures how successful these therapies are at fighting cancer, as well as their overall effect on a patient’s immune system. Dr. Kalos’ lab can determine if the treatment worked, or if subtle changes need to be made to generate a better chance of success.
The correlative studies program is a vital part of City of Hope’s vision of the future of cancer treatment: therapies crafted on the genetic level to meet the precise, individual needs of specific cancer patients. It’s more evidence of how you are helping create tomorrow’s answers to cancer, through your generous partnership with City of Hope today.
